Biopharmaceutical firm Orphazyme (NASDAQ:ORPH) has emerged as a major gainer over the course of the past two days and in the past two trading sessions the stock has managed to clock gains of 50%. ‘
In light of the sort of gains recorded by the stock in the past two sessions, it could be a good time for investors to look into it a bit more closely. There has been no news about the company in recent days but investors have flocked to the stock in a big way and sent it soaring. In this context, it is perhaps also necessary to point out that in the past the Orphazyme stock has recorded such volatile spikes in the past well.
It seems that the latest rally in the stock is driven by the anticipation among investors with regards to the publication of the interim results for one of its products. The company is all set to publish the H1 Interim Report on August 31 and in the lead up to that date, investors seem to be piling on to the Orphazyme stock. At this point in time, it might be a good idea for investors to keep the stock in their watch lists.